A Phase I/II Study of Evaluate the Safety and Efficacy of HLCR011 in Patients with Retinal Pigment Epithelium Tear

Sumitomo Pharma Co.,Ltd.0 个研究点目标入组 22 人开始时间: 2024年4月11日最近更新: 2025年2月5日

试验速览

暂无简介。

•The subjects who fulfill the following criteria will be included in the study.
•RPE tear (the longest diameter greater than 1 disc diameter) secondary to neovascular age-related macular degeneration or other retinal diseases (regardless of the cause) by fundus photography (including spontaneous fluorescence) and OCT in the study eye
•Age of 18 years or older at the time of informed consent
•RPE tear confirmed within 9 months before informed consent
•BCVA of >=24 and =<78 letters using the ETDRS chart in the study eye at screening and baseline
•Women of childbearing potential who have a negative (urine) pregnancy test at screening.
•Patients who agree to use appropriate contraception during the study period to prevent pregnancy in them or their female partners if the patients or their female partners are of childbearing potential

•The subjects who meet any of the following criteria will be excluded from the study.
•Patients with neovascularization that is attributable to causes other than neovascular age-related macular degeneration, such as high myopia (spherical equivalent=<-8 diopter or axial length >=26 mm) in the study eye
•A history of vitreous surgery for macular lesions in the study eye
•Macular hole in the study eye
•Macular lesions that may restrict visual acuity or visual field in the study eye (e.g., significant epiretinal membrane, advanced glaucoma, except for neovascular age-related macular degeneration and retinal pigment epithelium tear)
•Patients with poorly controlled systemic diseases
•Women who are pregnant, may be pregnant, or are lactating
•A history of allergy or hypersensitivity to study procedures/medications except for anesthetics, antiseptics and mydriatics which can be replaced with others
•Patients considered by the Investigator to be inappropriate as subjects of this study

Number and proportion of subjects with adverse events

未报告次要终点

发起方

Sumitomo Pharma Co.,Ltd.